Kyle T. Mincham
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Kyle T. Mincham has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
- Deborah H. Strickland
Telethon Kids Institute
18 shared publications - Patrick G. Holt
Wal-yan Respiratory Research Centre, The Kids Research Institute Australia, Nedlands, Western Australia, Australia
8 shared publications - Jean-François Lauzon-Joset
Centre de Recherche de l'IUCPQ - Université Laval, Québec, QC, Canada
7 shared publications - Robert J. Snelgrove
Inflammation Repair and Development, National Heart and Lung Institute, Imperial College London, London SW7 2AZ, UK
6 shared publications Jean-Francois Lauzon-Joset
Wal-yan Respiratory Research Centre, Telethon Kids Institute, Nedlands, Western Australia, Australia
5 shared publications- Jonatan Leffler
The Kids Research Institute Australia, University of Western Australia Perth Western Australia Australia
5 shared publications
Latest Publications
- 1 October 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (818) , eadu4913
Severe asthma is characterized by a sex-specific ILC landscape and aberrant airway profile that is suppressed by anti–IL-5/5Rα biologics
Innate lymphoid cells (ILCs) fulfill critical roles in maintenance of tissue-specific homeostasis but have also been implicated in disease pathology when dysregulated. Although they are broadly classified into three core subsets, it is increasingly apparent that ILCs exhibit plasticity in response to microenvironmental factors. Accurate and holistic evaluation of the ILC landscape is critical to understanding the contribution of ILCs to disease pathology. Using high-parameter flow cytometry, we comprehensively interrogated the phenotypic and functional diversity of ILCs in healthy volunteers and patients with severe asthma (SA), assessing the reciprocity between peripheral blood and airway compartments and dissecting the impact of anti–IL-5/5Rα biologics on these responses. We identified substantial heterogeneity and putative plasticity in human ILC responses, highlighting inherent limitations of conventional enumeration strategies. Deep phenotypic and functional profiling demonstrated a distinct sexual dimorphism in ILC responses in patients with SA. Females displayed an elevated abundance of circulating ILC progenitors, ILC1s, and ILC3s, whereas males presented with diminished ILC2s compared with respective healthy controls. Circulating ILC progenitors inversely correlated with testosterone concentrations. Moreover, we identified a reciprocal influx of all core ILC subsets into the airways of patients with SA, with unbiased multisource clustering identifying a relationship between elevated airway ILC2s and reduced lung function. Last, we showed that anti–IL-5/5Rα biologics largely ablated airway ILC type 2 cytokine production without affecting core ILC subset abundance in the peripheral blood or airways, identifying a potential mechanism whereby anti–IL-5/5Rα biologics alleviate clinical disease in patients with SA.
- 1 October 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (818) , eadu4913
Severe asthma is characterized by a sex-specific ILC landscape and aberrant airway profile that is suppressed by anti–IL-5/5Rα biologics
Innate lymphoid cells (ILCs) fulfill critical roles in maintenance of tissue-specific homeostasis but have also been implicated in disease pathology when dysregulated. Although they are broadly classified into three core subsets, it is increasingly apparent that ILCs exhibit plasticity in response to microenvironmental factors. Accurate and holistic evaluation of the ILC landscape is critical to understanding the contribution of ILCs to disease pathology. Using high-parameter flow cytometry, we comprehensively interrogated the phenotypic and functional diversity of ILCs in healthy volunteers and patients with severe asthma (SA), assessing the reciprocity between peripheral blood and airway compartments and dissecting the impact of anti–IL-5/5Rα biologics on these responses. We identified substantial heterogeneity and putative plasticity in human ILC responses, highlighting inherent limitations of conventional enumeration strategies. Deep phenotypic and functional profiling demonstrated a distinct sexual dimorphism in ILC responses in patients with SA. Females displayed an elevated abundance of circulating ILC progenitors, ILC1s, and ILC3s, whereas males presented with diminished ILC2s compared with respective healthy controls. Circulating ILC progenitors inversely correlated with testosterone concentrations. Moreover, we identified a reciprocal influx of all core ILC subsets into the airways of patients with SA, with unbiased multisource clustering identifying a relationship between elevated airway ILC2s and reduced lung function. Last, we showed that anti–IL-5/5Rα biologics largely ablated airway ILC type 2 cytokine production without affecting core ILC subset abundance in the peripheral blood or airways, identifying a potential mechanism whereby anti–IL-5/5Rα biologics alleviate clinical disease in patients with SA.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA3536
Heterogeneous ILC responses in severe asthma patients undergoing anti-IL5/5Ra therapy
Rationale: Innate lymphoid cells (ILCs) are a heterogeneous group of effector cells. Asthma is classically a type 2 disease, and dysregulated ILC2s are implicated in pathology. However, severe asthma (SA) is a heterogeneous disease, for which there is little known about the role of other ILC subsets. This study sought to exhaustively characterise ILCs in SA relative to healthy controls (HC), and infer the impact of anti-IL5/5Ra therapy on these populations. Methods: Patient demographics, spirometry and FeNO were prospectively collected with blood and induced sputum from HCs (n=20) and SA subjects pre and post benralizumab/mepolizumab (n=26) for ≥3 months. 21-colour full-spectrum flow cytometry was used for ILC evaluation and proteomics performed via Olink. Results: SA was associated with increased ILC progenitors (ILCPs) in the blood and sputum, as well as elevated T-bet+ ILC1s, GATA-3+ ILC2s and RORγt+ ILC3s within the airways only of SA subjects. Increased sputum ILCP, ILC1 and ILC2 populations correlated with ACQ-7 score and FEV1 % predicted. Anti-IL5/5Ra therapy did not alter ILC subset numbers in the blood or sputum, however there was a reduction in ILCs displaying type 2 features within the airways. Proteomic profiling highlighted a significant positive correlation between total ILCs within the airways of SA subjects and expression of the type 2-associated cytokines IL-5, IL-13 and IL-33, with all correlations absent following anti-IL5/5Ra therapy. Conclusion: SA subjects exhibit a multifaceted ILC subset response in their airways that correlates with type 2 cytokines and clinical prognosis. Importantly, pathogenic airways ILC2 responses are selectively dampened following anti-IL5/5Ra therapy.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA3536
Heterogeneous ILC responses in severe asthma patients undergoing anti-IL5/5Ra therapy
Rationale: Innate lymphoid cells (ILCs) are a heterogeneous group of effector cells. Asthma is classically a type 2 disease, and dysregulated ILC2s are implicated in pathology. However, severe asthma (SA) is a heterogeneous disease, for which there is little known about the role of other ILC subsets. This study sought to exhaustively characterise ILCs in SA relative to healthy controls (HC), and infer the impact of anti-IL5/5Ra therapy on these populations. Methods: Patient demographics, spirometry and FeNO were prospectively collected with blood and induced sputum from HCs (n=20) and SA subjects pre and post benralizumab/mepolizumab (n=26) for ≥3 months. 21-colour full-spectrum flow cytometry was used for ILC evaluation and proteomics performed via Olink. Results: SA was associated with increased ILC progenitors (ILCPs) in the blood and sputum, as well as elevated T-bet+ ILC1s, GATA-3+ ILC2s and RORγt+ ILC3s within the airways only of SA subjects. Increased sputum ILCP, ILC1 and ILC2 populations correlated with ACQ-7 score and FEV1 % predicted. Anti-IL5/5Ra therapy did not alter ILC subset numbers in the blood or sputum, however there was a reduction in ILCs displaying type 2 features within the airways. Proteomic profiling highlighted a significant positive correlation between total ILCs within the airways of SA subjects and expression of the type 2-associated cytokines IL-5, IL-13 and IL-33, with all correlations absent following anti-IL5/5Ra therapy. Conclusion: SA subjects exhibit a multifaceted ILC subset response in their airways that correlates with type 2 cytokines and clinical prognosis. Importantly, pathogenic airways ILC2 responses are selectively dampened following anti-IL5/5Ra therapy.
- Open Access
- 1 September 2024
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 210 (5) , 533-535
NO Casting of NETs in Allergic Asthma
- 1 September 2024
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 210 (5) , 533-535
Open AccessNO Casting of NETs in Allergic Asthma
- 1 August 2024
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 71 (2) , 219-228
Mapping Lung Hematopoietic Progenitors: Developmental Kinetics and Response to Influenza A Infection
The bone marrow is a specialized niche responsible for the maintenance of hematopoietic stem and progenitor cells during homeostasis and inflammation. Recent studies, however, have extended this essential role to the extramedullary and extravascular lung microenvironment. Here, we provide further evidence for a reservoir of hematopoietic stem and progenitor cells within the lung from Embryonic Day 18.5 until adulthood. These lung progenitors display distinct microenvironment-specific developmental kinetics compared with their bone marrow counterparts, exemplified by a rapid shift from a common myeloid to a megakaryocyte–erythrocyte progenitor–dominated niche with increasing age. In adult mice, influenza A viral infection results in a transient reduction in multipotent progenitors within the lungs, with a parallel increase in downstream granulocyte–monocyte progenitors and dendritic cell populations associated with acute viral infections. Our findings suggest that lung hematopoietic progenitors play a role in reestablishing immunological homeostasis in the respiratory mucosa, which may have significant clinical implications for maintaining pulmonary health after inflammatory perturbation.
- 1 August 2024
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 71 (2) , 219-228
Mapping Lung Hematopoietic Progenitors: Developmental Kinetics and Response to Influenza A Infection
The bone marrow is a specialized niche responsible for the maintenance of hematopoietic stem and progenitor cells during homeostasis and inflammation. Recent studies, however, have extended this essential role to the extramedullary and extravascular lung microenvironment. Here, we provide further evidence for a reservoir of hematopoietic stem and progenitor cells within the lung from Embryonic Day 18.5 until adulthood. These lung progenitors display distinct microenvironment-specific developmental kinetics compared with their bone marrow counterparts, exemplified by a rapid shift from a common myeloid to a megakaryocyte–erythrocyte progenitor–dominated niche with increasing age. In adult mice, influenza A viral infection results in a transient reduction in multipotent progenitors within the lungs, with a parallel increase in downstream granulocyte–monocyte progenitors and dendritic cell populations associated with acute viral infections. Our findings suggest that lung hematopoietic progenitors play a role in reestablishing immunological homeostasis in the respiratory mucosa, which may have significant clinical implications for maintaining pulmonary health after inflammatory perturbation.
- Open Access
- 9 July 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-14
Neutrophil extracellular traps promote immunopathogenesis of virus-induced COPD exacerbations
Respiratory viruses are a major trigger of exacerbations in chronic obstructive pulmonary disease (COPD). Airway neutrophilia is a hallmark feature of stable and exacerbated COPD but roles played by neutrophil extracellular traps (NETS) in driving disease pathogenesis are unclear. Here, using human studies of experimentally-induced and naturally-occurring exacerbations we identify that rhinovirus infection induces airway NET formation which is amplified in COPD and correlates with magnitude of inflammation and clinical exacerbation severity. We show that inhibiting NETosis protects mice from immunopathology in a model of virus-exacerbated COPD. NETs drive inflammation during exacerbations through release of double stranded DNA (dsDNA) and administration of DNAse in mice has similar protective effects. Thus, NETosis, through release of dsDNA, has a functional role in the pathogenesis of COPD exacerbations. These studies open up the potential for therapeutic targeting of NETs or dsDNA as a strategy for treating virus-exacerbated COPD.
- 9 July 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-14
Open AccessNeutrophil extracellular traps promote immunopathogenesis of virus-induced COPD exacerbations
Respiratory viruses are a major trigger of exacerbations in chronic obstructive pulmonary disease (COPD). Airway neutrophilia is a hallmark feature of stable and exacerbated COPD but roles played by neutrophil extracellular traps (NETS) in driving disease pathogenesis are unclear. Here, using human studies of experimentally-induced and naturally-occurring exacerbations we identify that rhinovirus infection induces airway NET formation which is amplified in COPD and correlates with magnitude of inflammation and clinical exacerbation severity. We show that inhibiting NETosis protects mice from immunopathology in a model of virus-exacerbated COPD. NETs drive inflammation during exacerbations through release of double stranded DNA (dsDNA) and administration of DNAse in mice has similar protective effects. Thus, NETosis, through release of dsDNA, has a functional role in the pathogenesis of COPD exacerbations. These studies open up the potential for therapeutic targeting of NETs or dsDNA as a strategy for treating virus-exacerbated COPD.
- Open Access
- 29 April 2024
- Published by Taylor & Francis in Experimental Lung Research
- Vol. 50 (1) , 118-126
Treatment with inhaled aerosolised ethanol reduces viral load and potentiates macrophage responses in an established influenza mouse model
Treatment options for viral lung infections are currently limited. We aimed to explore the safety and efficacy of inhaled ethanol in an influenza-infection mouse model. In a safety and tolerability experiment, 80 healthy female BALB/c mice (20 per group) were exposed to nebulized saline (control) or three concentrations of ethanol (40/60/80% ethanol v/v in water) for 3x30-minute periods, with a two-hour break between exposures. In a separate subsequent experiment, 40 Female BALB/c mice were nasally inoculated with 104.5 plaque-forming units of immediate virulence "Mem71" influenza. Infection was established for 48-h before commencing treatment in 4 groups of 10 mice with either nebulized saline (control) or one of 3 different concentrations of ethanol (40/60/80% ethanol v/v in water) for 3x30-minute periods daily over three consecutive days. In both experiments, mouse behavior, clinical scores, weight change, bronchoalveolar lavage cell viability, cellular composition, and cytokine levels, were assessed 24-h following the final exposure, with viral load also assessed after the second experiment. In uninfected BALB/c mice, 3x30-minute exposures to nebulized 40%, 60%, and 80% ethanol resulted in no significant differences in mouse weights, cell counts/viability, cytokines, or morphometry measures. In Mem71-influenza infected mice, we observed a dose-dependent reduction in viral load in the 80%-treated group and potentiation of macrophage numbers in the 60%- and 80%-treated groups, with no safety concerns. Our data provides support for inhaled ethanol as a candidate treatment for respiratory infections.
- 29 April 2024
- Published by Taylor & Francis in Experimental Lung Research
- Vol. 50 (1) , 118-126
Open AccessTreatment with inhaled aerosolised ethanol reduces viral load and potentiates macrophage responses in an established influenza mouse model
Treatment options for viral lung infections are currently limited. We aimed to explore the safety and efficacy of inhaled ethanol in an influenza-infection mouse model. In a safety and tolerability experiment, 80 healthy female BALB/c mice (20 per group) were exposed to nebulized saline (control) or three concentrations of ethanol (40/60/80% ethanol v/v in water) for 3x30-minute periods, with a two-hour break between exposures. In a separate subsequent experiment, 40 Female BALB/c mice were nasally inoculated with 104.5 plaque-forming units of immediate virulence "Mem71" influenza. Infection was established for 48-h before commencing treatment in 4 groups of 10 mice with either nebulized saline (control) or one of 3 different concentrations of ethanol (40/60/80% ethanol v/v in water) for 3x30-minute periods daily over three consecutive days. In both experiments, mouse behavior, clinical scores, weight change, bronchoalveolar lavage cell viability, cellular composition, and cytokine levels, were assessed 24-h following the final exposure, with viral load also assessed after the second experiment. In uninfected BALB/c mice, 3x30-minute exposures to nebulized 40%, 60%, and 80% ethanol resulted in no significant differences in mouse weights, cell counts/viability, cytokines, or morphometry measures. In Mem71-influenza infected mice, we observed a dose-dependent reduction in viral load in the 80%-treated group and potentiation of macrophage numbers in the 60%- and 80%-treated groups, with no safety concerns. Our data provides support for inhaled ethanol as a candidate treatment for respiratory infections.
- Open Access
Mapping lung hematopoietic progenitors: Developmental kinetics and response to Influenza A viral infection
The bone marrow is a specialised niche responsible for the maintenance of hematopoietic stem and progenitor cells during homeostasis and inflammation. Recent studies however have extended this essential role to the extramedullary and extravascular lung microenvironment. Here, we provide further evidence for a reservoir of hematopoietic stem and progenitor cells within the lung from embryonic day 18.5 until adulthood. These lung progenitors display distinct microenvironment-specific developmental kinetics compared to their bone marrow counterparts, exemplified by a rapid shift from a common myeloid to megakaryocyte-erythrocyte progenitor dominated niche with increasing age. In adult mice, Influenza A viral infection results in a transient reduction in multipotent progenitors within the lungs, with a parallel increase in downstream granulocyte-macrophage progenitors and dendritic cell populations associated with acute viral infections. Our findings suggest lung hematopoietic progenitors play a role in re-establishing immunological homeostasis in the respiratory mucosa, which may have significant clinical implications for maintaining pulmonary health following inflammatory perturbation.
Open AccessMapping lung hematopoietic progenitors: Developmental kinetics and response to Influenza A viral infection
The bone marrow is a specialised niche responsible for the maintenance of hematopoietic stem and progenitor cells during homeostasis and inflammation. Recent studies however have extended this essential role to the extramedullary and extravascular lung microenvironment. Here, we provide further evidence for a reservoir of hematopoietic stem and progenitor cells within the lung from embryonic day 18.5 until adulthood. These lung progenitors display distinct microenvironment-specific developmental kinetics compared to their bone marrow counterparts, exemplified by a rapid shift from a common myeloid to megakaryocyte-erythrocyte progenitor dominated niche with increasing age. In adult mice, Influenza A viral infection results in a transient reduction in multipotent progenitors within the lungs, with a parallel increase in downstream granulocyte-macrophage progenitors and dendritic cell populations associated with acute viral infections. Our findings suggest lung hematopoietic progenitors play a role in re-establishing immunological homeostasis in the respiratory mucosa, which may have significant clinical implications for maintaining pulmonary health following inflammatory perturbation.
- Open Access
CXCL17 binds efficaciously to glycosaminoglycans with the potential to modulate chemokine signalling
CXCL17 is a mucosally secreted protein, and the most recently identified human chemokine, an assignment based on protein fold prediction and chemotactic activity for leukocytes. However, these credentials have been the subject of much recent discussion and no experimental evidence has been presented regarding the definitive structure of CXCL17. In this study, we evaluated the structural and chemoattractant credentials of CXCL17 to better characterise this molecule, and gain deeper insights into its functional role as a glycosaminoglycan (GAG) binding protein. In the absence of structural information, in silico modelling techniques assessed the likelihood of CXCL17 adopting a chemokine-fold. Recombinant CXCL17 was synthesized in mammalian and prokaryotic systems. Modified Boyden chamber and real-time chemotaxis assays assessed the ability of CXCL17 to promote chemotaxis of murine splenocytes, human neutrophils and CXCR1-transfectants. The efficacy of CXCL17 binding to GAGs was quantified with solid-phase assays and bio-layer interferometry techniques. All modelling efforts failed to support classification of CXCL17 as a chemokine based on its predicted conformation. Recombinant CXCL17 was observed to dimerize as a function of concentration, a characteristic of several chemokines. Contrary to a previous report, CXCL17 was not chemotactic for murine splenocytes, although it was a low-potency chemoattractant for human neutrophils at micromolar concentrations, several orders of magnitude higher than those required for CXCL8. As anticipated due to its highly basic nature, CXCL17 bound to GAGs robustly, with key C-terminal motifs implicated in this process. While inactive via CXCR1, CXCL17 was found to inhibit CXCR1-mediated chemotaxis of transfectants to CXCL8 in a dose-dependent manner. In summary, despite finding little evidence for chemokine-like structure and function, CXCL17 readily bound GAGs, and could modulate chemotactic responses to another chemokine in vitro. We postulate that such modulation is a consequence of superior GAG-binding, and that C-terminal fragments of CXCL17 may serve as prototypic inhibitors of chemokine function.
Open AccessCXCL17 binds efficaciously to glycosaminoglycans with the potential to modulate chemokine signalling
CXCL17 is a mucosally secreted protein, and the most recently identified human chemokine, an assignment based on protein fold prediction and chemotactic activity for leukocytes. However, these credentials have been the subject of much recent discussion and no experimental evidence has been presented regarding the definitive structure of CXCL17. In this study, we evaluated the structural and chemoattractant credentials of CXCL17 to better characterise this molecule, and gain deeper insights into its functional role as a glycosaminoglycan (GAG) binding protein. In the absence of structural information, in silico modelling techniques assessed the likelihood of CXCL17 adopting a chemokine-fold. Recombinant CXCL17 was synthesized in mammalian and prokaryotic systems. Modified Boyden chamber and real-time chemotaxis assays assessed the ability of CXCL17 to promote chemotaxis of murine splenocytes, human neutrophils and CXCR1-transfectants. The efficacy of CXCL17 binding to GAGs was quantified with solid-phase assays and bio-layer interferometry techniques. All modelling efforts failed to support classification of CXCL17 as a chemokine based on its predicted conformation. Recombinant CXCL17 was observed to dimerize as a function of concentration, a characteristic of several chemokines. Contrary to a previous report, CXCL17 was not chemotactic for murine splenocytes, although it was a low-potency chemoattractant for human neutrophils at micromolar concentrations, several orders of magnitude higher than those required for CXCL8. As anticipated due to its highly basic nature, CXCL17 bound to GAGs robustly, with key C-terminal motifs implicated in this process. While inactive via CXCR1, CXCL17 was found to inhibit CXCR1-mediated chemotaxis of transfectants to CXCL8 in a dose-dependent manner. In summary, despite finding little evidence for chemokine-like structure and function, CXCL17 readily bound GAGs, and could modulate chemotactic responses to another chemokine in vitro. We postulate that such modulation is a consequence of superior GAG-binding, and that C-terminal fragments of CXCL17 may serve as prototypic inhibitors of chemokine function.
- Open Access
- 4 November 2022
- Published by Wiley in Cytometry Part A
- Vol. 103 (2) , 110-116
OMIP‐086: Full spectrum flow cytometry for high‐dimensional immunophenotyping of mouse innate lymphoid cells
This 25‐parameter, 22‐color full spectrum flow cytometry panel was designed and optimized for the comprehensive enumeration and functional characterization of innate lymphoid cell (ILC) subsets in mouse tissues. The panel presented here allows the discrimination of ILC progenitors (ILCP), ILC1, ILC2, NCR+ ILC3, NCR− ILC3, CCR6+ lymphoid tissue‐inducer (LTi)‐like ILC3 and mature natural killer (NK) cell populations. Further characterization of ILC and NK cell functional profiles in response to stimulation is provided by the inclusion of subset‐specific cytokine markers, and proliferation markers. Development and optimization of this panel was performed on freshly isolated cells from adult BALB/c lungs and small intestine lamina propria, and ex vivo stimulation with phorbol 12‐myrisate 13‐acetate, ionomycin, and pro‐ILC activating cytokines.
- 4 November 2022
- Published by Wiley in Cytometry Part A
- Vol. 103 (2) , 110-116
Open AccessOMIP‐086: Full spectrum flow cytometry for high‐dimensional immunophenotyping of mouse innate lymphoid cells
This 25‐parameter, 22‐color full spectrum flow cytometry panel was designed and optimized for the comprehensive enumeration and functional characterization of innate lymphoid cell (ILC) subsets in mouse tissues. The panel presented here allows the discrimination of ILC progenitors (ILCP), ILC1, ILC2, NCR+ ILC3, NCR− ILC3, CCR6+ lymphoid tissue‐inducer (LTi)‐like ILC3 and mature natural killer (NK) cell populations. Further characterization of ILC and NK cell functional profiles in response to stimulation is provided by the inclusion of subset‐specific cytokine markers, and proliferation markers. Development and optimization of this panel was performed on freshly isolated cells from adult BALB/c lungs and small intestine lamina propria, and ex vivo stimulation with phorbol 12‐myrisate 13‐acetate, ionomycin, and pro‐ILC activating cytokines.
- Open Access
Full Spectrum Flow Cytometry for High-Dimensional Immunophenotyping of Mouse Innate Lymphoid Cells
Purpose and appropriate sample types: This 25-parameter, 22-colour full spectrum flow cytometry panel was designed and optimised for the comprehensive enumeration and functional characterisation of innate lymphoid cell (ILC) subsets in mouse tissues (Table 1). The panel presented here allows the discrimination of ILC progenitors (ILCP), ILC1, ILC2, NCR + ILC3, NCR − ILC3, CCR6 + lymphoid tissue-inducer (LTi)-like ILC3 and mature natural killer (NK) cell populations. Further characterisation of ILC and NK cell functional profiles in response to stimulation is provided by the inclusion of subset-specific cytokine markers, and proliferation markers. Development and optimisation of this panel was performed on freshly isolated cells from adult BALB/c lungs and small intestine lamina propria, and ex vivo stimulation with phorbol 12-myrisate 13-acetate, ionomycin and pro-ILC activating cytokines. Ethical compliance statement: All mouse experiments were performed in accordance with the recommendations in the Guide for the Use of Laboratory Animals of Imperial College London, with the ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines. All animal procedures and care conformed strictly to the UK Home Office Guidelines under the Animals (Scientific Procedures) Act 1986, and the protocols were approved by the Home Office of Great Britain.
Open AccessFull Spectrum Flow Cytometry for High-Dimensional Immunophenotyping of Mouse Innate Lymphoid Cells
Purpose and appropriate sample types: This 25-parameter, 22-colour full spectrum flow cytometry panel was designed and optimised for the comprehensive enumeration and functional characterisation of innate lymphoid cell (ILC) subsets in mouse tissues (Table 1). The panel presented here allows the discrimination of ILC progenitors (ILCP), ILC1, ILC2, NCR + ILC3, NCR − ILC3, CCR6 + lymphoid tissue-inducer (LTi)-like ILC3 and mature natural killer (NK) cell populations. Further characterisation of ILC and NK cell functional profiles in response to stimulation is provided by the inclusion of subset-specific cytokine markers, and proliferation markers. Development and optimisation of this panel was performed on freshly isolated cells from adult BALB/c lungs and small intestine lamina propria, and ex vivo stimulation with phorbol 12-myrisate 13-acetate, ionomycin and pro-ILC activating cytokines. Ethical compliance statement: All mouse experiments were performed in accordance with the recommendations in the Guide for the Use of Laboratory Animals of Imperial College London, with the ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines. All animal procedures and care conformed strictly to the UK Home Office Guidelines under the Animals (Scientific Procedures) Act 1986, and the protocols were approved by the Home Office of Great Britain.